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Cellular and phenotypic plasticity is a key feature of development and normal function of cells
withinmostmulticellular organisms. The ability to respond to various intrinsic and external cues and
stimuli in a regulated fashion allows for appropriate cellular adjustments. This plasticity observed in
most cell types is retained in cancer and can lead to opportunistic adaptation allowing therapeutic
escape and acquisition of motile and invasive abilities that pose ongoing challenges for effective
therapy. The dynamic nature of this plasticity and the apparent requirement for widely divergent
phenotypes for different aspects of the metastatic cascade (e.g., initial escape – mesenchymal and
distant colonization – epithelial) is especially challenging.
The consequences and functional outcomes of this plasticity are well-studied and widely reported
in relation to epithelial–mesenchymal transition (EMT). In normal and cancer cells alike, EMT
is regulated through signaling pathways (1), the outcome of which is dictated by the balance and
cross-talk between the pathways as reviewed within this Research Topic (2). EMT is classically
defined as a dynamic, multistep cellular process that allows non-motile, highly organized and
polarized epithelial cells to acquire motile and more fibroblast-like, mesenchymal characteristics. It
is accompanied by the loss of some epithelial characteristics including specialized cell–cell junctions
and apical-basal polarity, and a complex reorganization of the cellular cytoskeleton (3). Functional
consequences of EMT, including enhanced or acquired migratory capacity, can result in the release
of tumor cells into circulation (4) and ultimately metastasis of the cancer. Not all cells within
a tumor undergo EMT, as different signaling inputs at different tumor sites or a variation in
genetic drivers in different clones can lead to different cellular states. However, EMT and EMT-
like processes contribute greatly to tumor heterogeneity, the challenges of which are highlighted for
colorectal cancer within this Research Topic (5). EMT-like phenotype-switching processes have also
been described in non-epithelial cancers, such as in melanoma (6). As reviewed in this Research
Topic (7), this can involve similar EMT inducers and EMT-transcription factors (EMT-TFs), but
variable patterns in terms of expression. Also, unlike the more distinct differences seen after EMT
in development, carcinoma systems often exhibit a partial EMT, sometimes called a metastable
or hybrid phenotype, reinforcing the concept of dynamic epithelial–mesenchymal plasticity
(EMP) (3, 8, 9).
Besides the already mentioned functional changes, tumor cells can undergo changing antigen
patterns in a dynamic process parallel to phenotype switching (10), allowing for escape from
recognition by already primed cytotoxic T lymphocytes (CTLs) and resulting in immune evasion.
Thus, while adaptive as well, the immune system needs to constantly re-adjust, just one of the many
obstacles for immune-based tumor control.
Recently, there has been an expanding body of research linking EMT and the mesenchymal-like
phenotypic state of cells to therapy resistance. In the case of epithelial cancers, such as breast
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and colorectal cancers, elevated expression ofmesenchymalmark-
ers or alterations to mesenchymal phenotypes has been shown to
be associated with increased metastasis (11) and poor response to
treatment (12). Cancer cells in a more mesenchymal-like state are
more refractory to conventional cytotoxic therapies, to radiation,
and to targeted therapies (13, 14). The exact mechanism of sur-
vival in these cells is not yet clear. It is possible that phenotypic
mediators can confer survival or anti-apoptotic signals, or possi-
bly the altered phenotypic state usually associated with reduced
proliferation renders them refractory to cell death following
treatment.
The extent of changes within the proteome and signaling net-
works of cancer cells, particularly in the context of acquired resis-
tance to targeted therapies (driven by genetic changes), is broad
and exemplified in this Research Topic by a phospho-proteomics
study of melanoma cells resistant to BRAF inhibitor therapy (15).
Experience from the clinic of patients relapsing within months of
BRAF-inhibitor treatment demonstrates the challenging clinical
implications of this complexity (7).
Cancer cells do not exist in isolation. They are in direct contact
with stromal cells and an intense crosstalk between “normal” cells
and cancer cells is constantly occurring. The tumor microen-
vironment is regulated by factors produced by both the tumor
and the stromal cells (5) and is not limited to close proximity.
In recent years it has been demonstrated that primary tumors
can establish favorable conditions for future metastasis in distant
organs. The so-called pre-metastatic niche can be formed by
non-tumorigenic host cells, cytokines, and tumor-derived exo-
somes, small extracellular vesicles that transfer information froma
tumor to other cells as reviewed by Vella (16), thereby influencing
other cellular compartments for promotion of tumor growth and
metastasis (17).
Based on these data, it is clear that prevention of a phenotypic
switch to this refractory state or reversal to an epithelial-like
state (MET) that would restore proliferative capacity may pro-
vide a means for maintaining or enhancing drug responsiveness,
and possibly even reducing heterogeneity. Hence, identifying the
molecular drivers that induce or maintain the mesenchymal-like
phenotype, provides an opportunity for “drugging” this pheno-
typic drug-resistant state, through inhibition of the key signaling
pathways that regulate the critical EMT-inducers (12, 18, 19).
This approach must be tempered with the risk that reversion to a
proliferativeMET state will increase tumor burden if the therapies
delivered are not sufficiently effective. Our understanding of the
balance, regulation, and cross-talk between the pathways intrin-
sically within the cancer cells, as well as extrinsically in relation
to the tumor microenvironment, is revealing opportunities for
multi-modality therapies. The identification of potential biomark-
ers of cell state and drug response will also help to guide the
choice of therapy and timing for individualized treatment for each
patient. The use of novel, multi-cellular organisms for expanding
our understanding of these processes (20) is a necessary path to
advance research discoveries in this area.
With a better understanding of the processes implicated in
cancer progression, and the key regulatory elements, options for
improved therapeutic strategies can be designed to specifically
predict and exploit the plasticity of cancer cells. As we move
from an era of DNA damaging therapy into an era of combi-
nation multi-modality treatments, the focus of the therapeutic
target shifts from just the tumor type or the genetic alteration,
to the interplay between oncogenic drivers, the vasculature, the
microenvironment, and, most promisingly, the immune system.
Understanding this complex interplay and the adaptive changes
induced by therapy, within the tumor cells as well as within
interacting compartments, is an undeniably important aspect of
current and future research efforts toward effective treatment to
control, and hopefully cure, cancer.
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